The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)

NCT ID: NCT07303868

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-07-31

Study Completion Date

2030-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using a four-week randomized, crossover study design, we will assess the impact of 2 weeks of a high bile acid-binding blenderized diet, compared to 2 weeks of a low bile acid-binding blenderized diet, on gastric and salivary bile acid concentrations within individual participants. Four weeks of an amino acid formula will be a comparator group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Feeding Difficulties Gastrostomy Aspiration

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

blenderized bile acid gastrostomy aspiration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low bile binding then high bile binding blenderized diets

2 weeks of low bile binding then 2 weeks of high bile binding blenderized diets

Group Type EXPERIMENTAL

Low bile acid binding blenderized diet

Intervention Type DRUG

Low bile acid binding blenderized diet administered for 2 weeks

High bile acid binding blenderized diet

Intervention Type DRUG

High bile acid binding blenderized diet administered for 2 weeks

High bile binding then low bile binding blenderized diets

2 weeks of high bile binding then 2 weeks of low bile binding blenderized diets

Group Type EXPERIMENTAL

Low bile acid binding blenderized diet

Intervention Type DRUG

Low bile acid binding blenderized diet administered for 2 weeks

High bile acid binding blenderized diet

Intervention Type DRUG

High bile acid binding blenderized diet administered for 2 weeks

amino acid-based formula

Observational arm

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low bile acid binding blenderized diet

Low bile acid binding blenderized diet administered for 2 weeks

Intervention Type DRUG

High bile acid binding blenderized diet

High bile acid binding blenderized diet administered for 2 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* receive at least 80% of their nutritional needs via gastrostomy
* receive blenderized feeds or will start receiving blenderized feeds
* have no known allergies to ingredients in blenderized feeds;
* receive their bolus feeds within 30 minutes or less

Exclusion Criteria

* have undergone anti-reflux surgery
* receive post-pyloric feeds
* are allergic to any component of the administered diets
* cannot receive their gastrostomy feeds over 30 minutes
* require a feeding pump for feed administration (as the H-BBB is too thick for pump administration).

Pediatric patients ages 5 to 21 in the observational arm Inclusion

* receive at least 80% of their nutritional needs via gastrostomy
* are taking an amino acid formula
* have not undergone antireflux surgery Exclusion
* have undergone anti-reflux surgery
* receive post-pyloric feeds
* are not receiving an amino acid-based formula.
Minimum Eligible Age

5 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rachel Rosen

Director, Aerodigestive Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-P00049734 Aim 2

Identifier Type: -

Identifier Source: org_study_id